Reviva Pharmaceuticals: Phase 3 RECOVER study enrollment exceeds 80%; topline data expected Q3 2023

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Over 80% of patients enrolled in pivotal Phase 3 RECOVER study of brilaroxazine for schizophrenia; enrollment ongoing in US, Europe, Asia.
Topline data from the ~400-patient placebo-controlled trial expected in Q3 2023.
Company also reports $5.7M in gross proceeds from Q2 2023 warrant exercises: $4.74M from common warrants at $2.40/share and $0.915M from investor warrants at $4.125/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.